Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer

Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated treatment-naive RET fusion-positive non-small-cell lung cancer patients Phase I/II clinical trial. LIBRETTO-431 (NCT04194944) is randomized, global, multicenter, open-label, III trial, evaluating selpercatinib versus carboplatin or cisplatin pemetrexed chemotherapy without pembrolizumab locally advanced/metastatic nonsquamous cancer. The primary end point progression-free survival by independent review. Key secondary points include overall survival, response rate, duration survival. Clinical trial registration: NCT04194944 (ClinicalTrials.gov)